LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

Search

Celldex Therapeutics Inc

Open

SectorHealthcare

20.7 1.07

Overview

Share price change

24h

Current

Min

19.97

Max

21.2

Key metrics

By Trading Economics

Income

-6.7M

-54M

Sales

-480K

695K

EPS

-0.81

Profit margin

-7,740.432

Employees

186

EBITDA

-6.7M

-62M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+164.83% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

65M

1.4B

Previous open

19.63

Previous close

20.7

News Sentiment

By Acuity

50%

50%

134 / 381 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Celldex Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 cze 2025, 18:52 UTC

Earnings

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

22 cze 2025, 23:59 UTC

Market Talk

Gold Edges Higher Amid Worries Over Middle East Conflict -- Market Talk

22 cze 2025, 23:55 UTC

Market Talk

Markets Wait to See if Iran's Response Will be Symbolic or Substantial -- Market Talk

22 cze 2025, 23:51 UTC

Market Talk

Oil Climbs After U.S. Attack on Iran's Nuclear Sites -- Market Talk

22 cze 2025, 23:43 UTC

Market Talk

Reasons to Believe Strait of Hormuz Will Remain Open -- Market Talk

22 cze 2025, 23:38 UTC

Market Talk

Nikkei May Fall as Middle East Uncertainty Persists -- Market Talk

22 cze 2025, 23:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 cze 2025, 23:11 UTC

Market Talk

Early Market Reaction to Iran Attacks Restrained -- Market Talk

22 cze 2025, 22:59 UTC

Market Talk

Gold, Silver Rise as Investors Seek Haven After Strikes on Iran -- Market Talk

22 cze 2025, 21:43 UTC

Market Talk

Australian Govt Says Supports US Strikes On Iran -- Market Talk

21 cze 2025, 08:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

21 cze 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

21 cze 2025, 08:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

20 cze 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

20 cze 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

20 cze 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 cze 2025, 20:13 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 cze 2025, 20:11 UTC

Market Talk

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20 cze 2025, 19:56 UTC

Market Talk

Crude Oil Slips to End Week -- Market Talk

20 cze 2025, 18:35 UTC

Market Talk

Warehouse Clubs Seen Growing Market Share -- Market Talk

20 cze 2025, 18:12 UTC

Market Talk

Gold Slides to Close Shortened Week -- Market Talk

20 cze 2025, 17:56 UTC

Market Talk

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20 cze 2025, 17:50 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 cze 2025, 17:35 UTC

Acquisitions, Mergers, Takeovers

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20 cze 2025, 17:30 UTC

Market Talk
Earnings

Adobe's AI Headwinds Seen Fading -- Market Talk

20 cze 2025, 17:03 UTC

Earnings

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20 cze 2025, 16:50 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

20 cze 2025, 16:50 UTC

Market Talk
Earnings

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20 cze 2025, 16:44 UTC

Acquisitions, Mergers, Takeovers

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20 cze 2025, 16:40 UTC

Market Talk
Earnings

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

164.83% upside

12 Months Forecast

Average 54.29 USD  164.83%

High 74 USD

Low 38 USD

Based on 9 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

134 / 381 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.